Censo Biotechnologies enables the discovery and development of new targeted treatments for disease by using stem cell technology to predict how drugs will behave across a given population.

Censo Biotechnologies Ltd is a stem cell technology company providing human cells and contract research services for drug discovery, toxicity testing and cell banking.

The company has the capabilities to generate induced pluripotent stem cells (iPSCs) from large cohorts of individuals and use the potential of these cells to create virtually any cell in the human body.

By developing cell-based models of disease using cells from a diverse range of tissue donors, the company supports the development of new targeted treatments for disease. Its major focus is the generation of novel data on drug efficacy and drug response variation for a given population.

The company was founded in 2016, through the merger of Roslin Cellab and Roslin Cell Sciences, and has facilities in both Edinburgh and Cambridge, UK.